Abstract
Sarcoidosis is an idiopathic granulomatous disease that occurs worldwide and may affect
any organ. Because the presenting symptoms of sarcoidosis are not specific for the
disease, the primary care physician is usually the first provider to assess these
patients. In addition, patients who have previously been diagnosed with sarcoidosis
are usually followed longitudinally by primary care physicians. Therefore, these physicians
are often the first to address sarcoidosis patient symptoms related to exacerbations
of the disease, as well as first observe complications of sarcoidosis medications.
This article outlines the approach to the evaluation, treatment and monitoring of
sarcoidosis patients by the primary care physician.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Sarcoidosis in America. Analysis Based on Health Care Use.Annals of the American Thoracic Society. 13. 2016: 1244-1252
- Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline.American journal of respiratory and critical care medicine. 2020; 201: e26-e51
- Sarcoidosis Diagnostic Score: A Systematic Evaluation to Enhance the Diagnosis of Sarcoidosis.Chest. 2018;
- How many organs need to be involved to diagnose sarcoidosis?: An unanswered question that, hopefully, will become irrelevant.Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31: 6-7
- The time bomb of isolated cardiac sarcoidosis: Is it ticking?.International journal of cardiology. 2022; 347: 62-63
- The Diagnosis of Sarcoidosis: Attempting to Apply Rigor to Arbitrary and Circular Reasoning.Chest. 2018; 154: 1006-1007
- There is no diagnosis of exclusion in rheumatology.Rheumatology (Oxford). 2022; 62: 1-2
- Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations.The American journal of the medical sciences. 2010; 339: 1-4
- Endobronchial biopsy for sarcoidosis: a prospective study.Chest. 2001; 120: 109-114
- Distinguishing asthma from sarcoidosis: an approach to a problem that is not always solvable.J Asthma. 2013; 50: 1-6
- Lofgren's syndrome revisited: a study of 186 patients.The American journal of medicine. 1999; 107: 240-245
- Lofgren's syndrome: human leukocyte antigen strongly influences the disease course.American journal of respiratory and critical care medicine. 2009; 179: 307-312
- Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review.Journal of the American College of Cardiology. 2020; 76: 1878-1901
- The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States.Sarcoidosis Vasc Diffuse Lung Dis. 2012; 29: 119-127
- The Clinical Features of Sarcoidosis: A Comprehensive Review.Clinical reviews in allergy & immunology. 2015; 49: 63-78
- Management of Advanced Pulmonary Sarcoidosis.American journal of respiratory and critical care medicine. 2022; 205: 495-506
- Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry.Eur Respir J. 2020; 55
- Chronic pulmonary aspergillosis complicating sarcoidosis.Eur Respir J. 2017; 49
- Wolff K Goldsmith LA Katz SI Gilchrest BA Paller AS Leffell DJ 7th ed. McGraw Hill Medical, New York2008: 1484-1493 (Vol 2)
- Cutaneous Sarcoidosis.Seminars in respiratory and critical care medicine. 2020; 41: 689-699
- Ocular sarcoidosis. Seminars in respiratory and critical care medicine. 2010; 31: 452-462
- Clinical aspects of ocular sarcoidosis.European Respiratory Journal Monograph. 2005; 10: 188-209
- Ocular manifestations of sarcoidosis.Sem Resp Crit Care Med. 2002; 23: 543-548
- Lacrimal gland involvement in sarcoidosis. The clinical features of 9 patients.Swiss medical weekly. 2003; 133: 388-391
- Renal sarcoidosis and hypercalcemia.European Respiratory Journal Monograph. 2005; 32: 220-232
- Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis.The Journal of experimental medicine. 1985; 161: 755-765
- Screening Sarcoidosis Patients for Occult Disease.Seminars in respiratory and critical care medicine. 2020; 41: 741-757
- Pathophysiology and clinical management of cardiac sarcoidosis.Nature reviews. Cardiology. 2015; 12: 278-288
- Clinical characteristics of patients in a case control study of sarcoidosis.American journal of respiratory and critical care medicine. 2001; 164: 1885-1889
- Causes of death in patients with chronic sarcoidosis.Sarcoidosis Vasc Diffuse Lung Dis. 2016; 33: 275-280
- Mortality in sarcoidosis. A changing pattern of the causes of death.European journal of respiratory diseases. 1981; 62: 231-238
- Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes.The American journal of cardiology. 2009; 104: 571-577
- Screening sarcoidosis patients for cardiac sarcoidosis: What the data really show.Respiratory medicine. 2019; 154: 155-157
- Management of cardiac sarcoidosis in the United States: a Delphi study.Chest. 2012; 141: 154-162
- The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology.Eur Heart J. 2007; 28: 3076-3093
- Clinical Course of Sarcoidosis in World Trade Center-Exposed Firefighters.Chest. 2018; 153: 114-123
- Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis.JACC Cardiovasc Imaging. 2017; 10: 1437-1447
- The three tiers of screening for sarcoidosis organ involvement.Respiratory medicine. 2016; 113: 42-49
- Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity.International immunology. 2005; 17: 1505-1512
- Pathology of sarcoidosis.Clinics in chest medicine. 1997; 18: 741-754
- The interleukin-2/interleukin-2 receptor system: structural, immunological, and clinical features.International journal of clinical & laboratory research. 1992; 22: 133-142
- Biomarkers in sarcoidosis.Expert Review of Clinical Immunology. 2016; 12: 1191-1208
- Effects of sarcoid and steroids on angiotensin-converting enzyme.The American review of respiratory disease. 1983; 128: 631-633
- Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation.Chest. 2003; 124: 186-195
- Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis.J Nucl Med. 1994; 35: 1647-1649
- Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis.Journal of the American College of Cardiology. 2014; 63: 329-336
- Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis.Chest. 2007; 132: 1949-1953
- Imaging manifestations of neurosarcoidosis.Ajr. 2004; 182: 289-295
- The indications for the treatment of sarcoidosis : Well's Law.Sarcoidosis Vasc Diff Lung Dis. 2017; 34: 280-282
- ERS clinical practice guidelines on treatment of sarcoidosis.Eur Respir J. 2021;
- Corticosteroids for pulmonary sarcoidosis.Cochrane Database Syst Rev. 2005; CD001114
- Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases.Respiration; international review of thoracic diseases. 1994; 61: 219-225
- The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases.Sarcoidosis Vasc Diffuse Lung Dis. 2000; 17: 158-166
- Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis.Eur Respir J. 1995; 8: 682-688
- Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis.European respiratory review : an official journal of the European Respiratory Society. 2020; 29
- Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease.Journal of the American Academy of Dermatology. 2012; 66 (699 e691-618; quiz 717-698)
- HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis.Heart rhythm : the official journal of the Heart Rhythm Society. 2014; 11: 1305-1324
- The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis.J Nucl Cardiol. 2017; 24: 19-28
- Small fibre neuropathy in sarcoidosis.Lancet. 2002; 359: 2085-2086
- Effects of meditation on pain and quality of life in multiple sclerosis and peripheral neuropathy: a pilot study.International journal of MS care. 2011; 13: 163-168
- Fatigue in sarcoidosis: a systematic review.Current opinion in pulmonary medicine. 2009; 15: 499-506
- Quality of life in sarcoidosis: assessment and management.Seminars in respiratory and critical care medicine. 2010; 31: 485-493
- [The Lofgren syndrome: acute sarcoidosis (author's transl)].Rontgenblatter. 1977; 30: 325-327
- Health-related quality of life of persons with sarcoidosis.Chest. 2004; 125: 997-1004
- Depression in sarcoidosis.American journal of respiratory and critical care medicine. 2001; 163: 329-334
- Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study.Respiratory medicine. 2018; 138s: S24-s30
Article info
Publication history
Accepted:
February 20,
2023
Received:
February 13,
2023
Publication stage
In Press Journal Pre-ProofFootnotes
Dr. Marc A. Judson is responsible for all content within this manuscript.
Funding: None
Conflicts of interest: The author is a consultant for Star Therapeutics. He has obtained grants for his institution from aTyr, Mallinckrodt, and Foundation for Sarcoidosis Research.
Identification
Copyright
© 2023 Published by Elsevier Inc.
